Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)

Huge Transport Trade Highlights Insider Buying: CSX, GE, Mattel, IFF and More

With first-quarter earnings winding down, but still in the process, the windows for insiders remain closed for the most part, so we had another week of lower volumes. However, with ...
Read Full Story »

Valeant, Arena Pharmaceuticals in Tuesday’s 52-Week Low Club

April 18, 2017: Here are four stocks trading with relatively heavy volume among 85 equities making new 52-week lows in Tuesday's session. On the NYSE, decliners led advancers by about ...
Read Full Story »

Arena Pharmaceuticals Sinks After Announcing Secondary Offering

Arena Pharmaceuticals Inc. (NASDAQ: ARNA) saw its shares drop sharply on Tuesday after the company announced a secondary offering. Arena plans to offer 60 million shares of its common stock ...
Read Full Story »

Wednesday’s Biggest Biopharma Movers

The broad markets inched forward on Wednesday after hitting new highs in what has been known as the Trump rally. Although the SPDR S&P Biotech ETF (NYSEMKT: XBI) was up ...
Read Full Story »
Woman holding hemp flowers, Marijuana plant, weed

The 10 Largest Marijuana Companies

The November election wound up with eight states added to the number of them where either medical or recreational marijuana (or both) are or will be legally for sale. Medical marijuana ...
Read Full Story »
biotech word cloud

Top 6 BioPharma Movers of the Week

Over the past week, a few biotech companies made absolutely massive runs. In the past year, the health care sector was on fire from positive trials, U.S. Food and Drug ...
Read Full Story »

Arena Pharma Soars on FDA Approval

Arena Pharmaceuticals Inc. (NASDAQ: ARNA) saw its shares jump in Monday’s session on news of an U.S. Food and Drug Administration (FDA) approval. The company announced that the FDA has ...
Read Full Story »
buy sell

5 Stocks That Should See Huge Buying on Russell Month-End Index Changes

All the major indexes rebalance share weightings on a regular basis, as price and market cap changes dictate either buying or selling of shares at a designated time. This Friday ...
Read Full Story »

Credit Suisse Positive on Some Biotechs, Very Cautious on Others

Credit Suisse has launched new biotech coverage on Wednesday with two analysts at the firm. The biotech sector has been a wealth-creation engine in recent years. What is interesting here ...
Read Full Story »

Orexigen Irony: No VIVUS Bounce

VIVUS Inc. (NASDAQ: VVUS) investors have a lot to be disappointed about these days. America's ballooning waistline is reaching a critical level, yet VIVUS did not even manage to close ...
Read Full Story »

Biotech Stocks Under $10 With Huge Upside Potential for 2014

Large cap biotech stocks have seen incredible stock performance over the past few years. The problem for many investors is that many of the key stocks have become so expensive ...
Read Full Story »
2014 in the box

Cowen Forecasts Top 10 Potential Biotech Surprises for 2014

All of the major firms on Wall Street we cover have prognostications and stock picks for 2014. The Cowen biotechnology team has a list of top 10 surprises that are ...
Read Full Story »
Bull and Bear

Top Analyst Upgrades and Downgrades: BlackBerry, Micron, SanDisk, VIVUS and More

With the government shut down and with the debt ceiling debate breathing down everyone's neck, investors have to be wondering what they should buy, sell and hold (or even avoid). ...
Read Full Story »
uncertainty market evolution

Jefferies Contrarian Stocks to Buy: Arena, Rackspace and More

It is not unusual to see most research on Wall Street pretty much line up either for or against a company. Analysts typically look at the same metrics in the ...
Read Full Story »
Bull and Bear figures

Closing Bell for Thursday on Wall Street: Markets Rise to New Highs on Jobs Report

U.S. equity markets opened higher this morning following upward revisions from the Bureau of Labor Statistics on non-farm payrolls in February and March and a larger-than-expected rise in payrolls in ...
Read Full Story »